The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| PRME | -14.02% | N/A | N/A | -77% |
| S&P | +13.96% | +91.24% | +13.85% | +86% |
Prime Medicine, Inc. is a biotechnology company, which engages in developing one-time curative genetic therapies. The company was founded by David R. Liu on September 13, 2019 and is headquartered in Cambridge, MA.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $1.23M | 486.1% |
| Gross Profit | -$0.66M | 51.4% |
| Gross Margin | -53.55% | 591.9% |
| Market Cap | $987.21M | 112.5% |
| Market Cap / Employee | $4.61M | 0.0% |
| Employees | 214 | -8.5% |
| Net Income | -$50.58M | 3.7% |
| EBITDA | -$52.09M | 1.1% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $71.40M | -39.5% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $110.42M | 200.4% |
| Short Term Debt | $7.71M | 72.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -54.98% | 21.7% |
| Return On Invested Capital | -72.40% | -7.6% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$35.29M | -29.8% |
| Operating Free Cash Flow | -$35.04M | -35.2% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 2.02 | 1.70 | 3.03 | 12.24 | 418.13% |
| Price to Sales | 116.10 | 67.72 | 64.32 | 148.77 | -74.32% |
| Price to Tangible Book Value | 2.02 | 1.70 | 3.03 | 12.24 | 418.13% |
| Enterprise Value to EBITDA | -4.63 | -4.68 | -6.54 | -15.24 | 143.89% |
| Return on Equity | -136.9% | -115.2% | -154.8% | -112.3% | -1.76% |
| Total Debt | $40.79M | $121.15M | $119.74M | $118.14M | 186.40% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
